Quite a few brokerage firms at Wall Street have predicted that the stocks of CLSD would be reporting a sales sum of $1 million for the quarter. According to several reports, three investment analysts covering the firm have already issued estimates into the earnings of CLSD. The range has gone all the way from $150,000 to $2.50 million. The pharmaceutical company did post revenue of $1.94 million the previous year, so this implies a negative annual growth rate of about 48.5%. CLSD would be issuing their next results on quarterly earnings on the 10th of March.
The Quarterly Earnings of CLSD
The shares of Clearside Biomedical did post their previous quarterly results on the 15th of November. The EPS reported by the company for that quarter was $0.05, which was compared with the consensus estimate set by Thomson Reuters of $0.12. The biomedical company had a negative 144.47% net margin rate, along with a negative 153.41% negative return on its equity. The revenue generated by the company during this quarter was $3.43 million.
There have been quite a few research equities that have commented on the stocks of CLSD. Needham & Company has already reiterated their rating of hold on the shares of this firm in a note that was published on the 11th of November. Zacks Investment Research has also increased the shares of the company from buy to sell, along with a price target set at $4.
Two investment analysts covering the firm have given it a rating of hold, while three of them have given CLSD a rating of buy. Currently, the target price on the company on an average is $5.75, while the rating has been set at Buy.
